A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Muscular Dystrophy Clinical Trial

Official title:

A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05230459
• Other study ID #: LION-CS101
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 12, 2023
• Est. completion date: December 2028

Study information

• Verified date: April 2024
• Source: Asklepios Biopharmaceutical, Inc.
• Contact: Medical Affairs at AskBio
• Phone: 919-561-6210
• Email: AskFirst[@]askbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I/R9 and confirmation of FKRP gene mutation.

2. Ability to ascend 4 stairs between 2.5 and 10 seconds.

3. Ability to walk/run 10 meters in < 30 seconds.

4. Able to understand and comply with all study procedures.

5. Sexually active females of childbearing potential and female and male partners of male subjects receiving AB-1003 must use a barrier method of contraception for the first 6 months after dosing.

Exclusion Criteria:

1. Significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction <40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and QTcF >480m/sec), NYHA Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of clinically important myocardial fibrosis.

2. Contraindication to MRI or hypersensitivity to contrast dyes, shellfish or iodine.

3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images.

4. History of chronic liver disease (e.g. hepatitis, HIV, steatosis) or abnormal liver function (abnormal GGT and/or abnormal total/direct bilirubin and/or AST and ALT >2 ULN).

5. Abnormal renal function (GFR < 60 ml/min, using the MDRD equation).

6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).

7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits.

8. Requirement for daytime ventilatory support.

9. Change in glucocorticosteroid treatment within 3 months prior to baseline visit.

10. Exposure to another investigational drug within 3 months prior to study treatment or any previous treatment with gene therapy.

11. Ongoing participation in any other therapeutic clinical trial.

12. Neutralizing antibody titer to AAV9 = 1:5.

13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or breastfeeding.

Related Conditions & MeSH terms

• LGMD2I
• Limb Girdle Muscular Dystrophy
• Limb-Girdle Muscular Dystrophy Type 2
• Muscular Dystrophies
• Muscular Dystrophy

Intervention

Genetic:
• AB-1003 dose level 1
Single intravenous infusion of AB-1003 gene therapy at dose level 1
• AB-1003 dose level 2
Single intravenous infusion of AB-1003 gene therapy at dose level 2

Other:
• Placebo
Single intravenous infusion of Placebo

Locations

Country	Name	City	State
United States	Kennedy Krieger Institute	Baltimore	Maryland
United States	University of Iowa	Iowa City	Iowa
United States	University of California - Irvine	Irvine	California
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	VCU	Richmond	Virginia
United States	University of Washington Medical Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Asklepios Biopharmaceutical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	Treatment Emergent Adverse Events, Serious Adverse Events, Dose Limiting Toxicity	0-52 weeks

External Links

•   Link to webpage for study and pre-qualification information